Author:
Soller Lianne,Abrams Elissa M.,Carr Stuart,Kapur Sandeep,Rex Gregory A.,Leo Sara,Lidman Per G.,Yeung Joanne,Vander Leek Timothy K.,McHenry Mary,Wong Tiffany,Cook Victoria E.,Hildebrand Kyla J.,Gerstner Thomas V.,Mak Raymond,Lee Nicole J.,Cameron Scott B.,Chan Edmond S.
Funder
BC Children’s Hospital Foundation
DBV Technologies
Novartis
AstraZeneca
Stallergenes Greer
Sanofi
Merck
Pfizer
Reference28 articles.
1. Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis;Nurmatov;Allergy,2017
2. Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: results of ARC001, a randomized, double-blind, placebo-controlled phase 2 clinical trial;Bird;J Allergy Clin Immunol Pract,2017
3. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective;Vickery;J Allergy Clin Immunol,2017
4. Efficacy, safety, and quality of life in a multi-center, randomized, placebo-controlled trial of low-dose peanut oral immunotherapy in peanut allergic children;Blumchen;J Allergy Clin Immunol Pract,2019
5. AR101 Oral immunotherapy for peanut allergy;Vickery;N Engl J Med,2018
Cited by
95 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献